Valuation: Nektar Therapeutics

Market Cap 111.33Cr 101.4Cr 93Cr 85Cr 159.45Cr 10TCr 167.58Cr 1.14TCr 451.98Cr 5.63TCr 417.73Cr 408.92Cr 18TCr P/E 2026 *
-4.54x
P/E 2027 * -3.33x
Enterprise Value 49Cr 45Cr 42Cr 38Cr 71Cr 4.58TCr 74Cr 505.51Cr 200.92Cr 2.5TCr 185.69Cr 181.77Cr 7.86TCr EV / Sales 2026 *
12.2x
EV / Sales 2027 * 13.3x
Free-Float
99.62%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%+1.97% - - 111.33Cr
-2.49%-6.35%+51.07%+64.95% 6.54TCr
-0.63%-3.81%+6.95%+88.55% 5.89TCr
-2.37%-2.22%+22.96%+83.44% 5.52TCr
-2.19%-6.02%+10.50%+109.19% 4.57TCr
-1.89%-9.33%+13.03%+20.04% 4.13TCr
-0.93%+1.67%+20.83%+45.03% 3.68TCr
+1.11%-8.59%+128.56%+655.74% 3.45TCr
-0.80%-1.73%+75.29%+56.47% 3.25TCr
-2.17%+19.70%-30.57%+469.42% 3.17TCr
Average -1.28%-0.66%+33.18%+176.98% 4TCr
Weighted average by Cap. -1.45%-1.28%+31.63%+151.41%

Financials

2026 *2027 *
Net sales 4.05Cr 3.69Cr 3.4Cr 3.09Cr 5.8Cr 375.25Cr 6.1Cr 41Cr 16Cr 204.96Cr 15Cr 15Cr 643.25Cr 5.12Cr 4.66Cr 4.29Cr 3.91Cr 7.33Cr 473.79Cr 7.7Cr 52Cr 21Cr 258.78Cr 19Cr 19Cr 812.16Cr
Net income -23Cr -21Cr -19Cr -17Cr -32Cr -2.1TCr -34Cr -231.1Cr -92Cr -1.14TCr -85Cr -83Cr -3.59TCr -35Cr -32Cr -30Cr -27Cr -51Cr -3.27TCr -53Cr -360.97Cr -143.47Cr -1.79TCr -132.59Cr -129.8Cr -5.61TCr
Net Debt -62Cr -56Cr -52Cr -47Cr -89Cr -5.73TCr -93Cr -631.7Cr -251.07Cr -3.13TCr -232.04Cr -227.15Cr -9.82TCr -43Cr -39Cr -36Cr -33Cr -62Cr -4TCr -65Cr -441.42Cr -175.44Cr -2.19TCr -162.14Cr -158.73Cr -6.86TCr
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Nektar Therapeutics